Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study

NCT07151456 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Phase

Phase 4

Started

2026-01

Last updated

2025-09-03

Condition(s) studied

Idiopathic Nephrotic Syndrome

Investigational drug(s) / intervention(s)

Conventional 24-week glucocorticoid regimenshort-term course (12 week) glucocorticoid regimen

Conventional 24-week glucocorticoid regimen: Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5 - 6: Prednisolone 0.8mg/kg/day (max 60mg); Weeks 7 - 8: Prednisolone 0.6mg/kg/day (max 50mg); Weeks 9 - 10: Prednisolone 0.5mg/kg/day (max 40mg); Weeks 11 - 12: Prednisolone 0.4mg/kg/day (max 30mg); Weeks 13 - 16: Prednisolone 0.3mg/kg/day (max 25mg); Weeks 17 - 20: Prednisolone 0.2mg/kg/day (max 15 Weeks 21 - 24: Prednisolone 0.1mg/kg/day (max 10mg).

short-term course (12 week) glucocorticoid regimen: Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5-8: Prednisolone 1mg/kg/day (max 80mg) on alternate days; 9-12: Prednisolone 0.5mg/kg/day (max 40mg) on alternate days

Study summary

This study will compare a short-term course (12 week) glucocorticoid regimen with the Conventional 24-week regimen as originally proposed by KDIGO. The purpose of the study is to determine a short-term course (12 week) of glucocorticoid decreases the time to first relapse in adults presenting with steroid sensitive nephrotic syndrome.

Eligibility

Sex

ALL

Min age

16 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Urine protein: creatinine ratio ≥3000mg/g (300mg/mmol) * Serum/plasma albumin level \< 30g/L * Age ≥ 16 years at the time of diagnosis * No prior therapy with steroids, immunosuppressive or cytotoxic agents for any form of renal disease (other than the 28 days of prednisolone therapy given initially as routine clinical practice) * No evidence of underlying systemic disorder or exposure to agents known to be associated with newly presenting steroid sensitive nephrotic syndrome * Informed consent * SSNS defined as Complete remission within 4 weeks of prednisone or prednisolone at standard dose Exclusion Criteria: * Secondary nephrotic syndrome * Contradictions for glucocorticoids * SRNS: Lack of complete remission within 4 weeks of therapy with daily prednisone or prednisolone at standard dose * anti-PLA2R positive * Adults with histological changes other than minimal lesion or focal segmental glomerular sclerosis (FSGS) glomerulonephritis where renal biopsy has been undertaken * Adults with a prior history of poor compliance with medical therapy Known allergy to glucocorticoid therapy * Other situations where the researcher deems it inappropriate to participate in the study

Primary outcome measure(s)

Relapse — through study completion, an average of 2 years
Relapse of proteinuria is defined by Albustix positive proteinuria (+++ or greater) for 3 consecutive days or the presence of generalised oedema plus 3+ proteinuria.

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	Zhejiang

More First Affiliated Hospital of Wenzhou Medical University trials in China

Intelligent Precision Knee Preservation System for Knee Osteoarthritis Starting soon

Preoperative vs Postoperative Revascularization in Coronary Heart Disease Patients Undergoing Time-Sensitive Non-Cardiac Surgery (CHRONOS-PCI) Starting soon

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety Recruiting

Study on Aging and Cognitive Impairment in China Recruiting

Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07151456 on ClinicalTrials.gov ↗ ← All trials in China